| Autor: |
Edavana VK; Division of Medical Genetics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, USA., Penney RB; Department of Environmental and Occupational Health, College of Public Health, Little Rock, USA., Yao-Borengasser A; Division of Medical Genetics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, USA., Starlard-Davenport A; Division of Medical Genetics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, USA., Dhakal IB; Division of Medical Genetics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, USA., Kadlubar S; Division of Medical Genetics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, USA. |
| Abstrakt: |
Anastrozole is an aromatase inhibitor (AI) used as adjuvant therapy for breast cancer. Anastrozole is subject to direct glucuronidation catalyzed by UDP-glucuronosyltransferase1A4 (UGT1A4). Interindividual variability in anastrozole glucuronidation may be affected by UGT1A4 SNPs. Interplay between drug metabolizing genes such as UGT1A4 and transporter genes may also be affected by genetic variability. Thus, we hypothesize that genetic variability in MRPs could influence anastrozole glucuronidation. The correlation between UGT1A4 and MRP2 or MRP3 transporter gene expressions and the correlation between MRP2 or MRP3 mRNA and anastrozole glucuronidation were analyzed in normal human liver samples. MRP2 and MRP3 mRNA levels were significantly correlated with UGT1A4 mRNA, with anastrozole glucuronidation and with each other (p<0.05). The data also demonstrated that MRP2 SNPs are positively correlated with MRP2 mRNA expression, while there was no association between MRP3 SNPs from this study and MRP3 expression. Significant correlations (p<0.05) between certain MRP2 SNPs (3972C>T, 2366C>T and -24C>T) and anastrozole glucuronidation were observed. There were no observed correlations between MRP3 SNPs and anastrozole glucuronidation. MRP2 polymorphisms have been identified as playing a role in the disposition of other drugs, and the data presented here indicate for the first time that MRP2 SNPs could influence anastrozole metabolism and contribute to interindividual variation in treatment responses. |
